tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Xbrane Biopharma Strengthens Focus with Sale of XB003 to Alvotech

Story Highlights
Xbrane Biopharma Strengthens Focus with Sale of XB003 to Alvotech

Elevate Your Investing Strategy:

Xbrane Biopharma AB ( (SE:XBRANE) ) just unveiled an update.

Xbrane Biopharma has completed the sale of its biosimilar candidate XB003 and parts of its organization to Alvotech for approximately SEK 275 million. This transaction strengthens Xbrane’s financial position, allowing the company to focus on its remaining programs, particularly Ximluci and Xdivane, and continue its work in biosimilar development to create value for shareholders and patients.

More about Xbrane Biopharma AB

Xbrane Biopharma AB is a company that develops biological drugs using a patented platform technology aimed at reducing production costs. The company has a portfolio of biosimilar candidates targeting significant market potential, with its lead candidate Ximluci® already launched in Europe. Xbrane is headquartered in Solna, Sweden, and is listed on Nasdaq Stockholm.

Average Trading Volume: 19,540,933

Current Market Cap: SEK362.8M

Learn more about XBRANE stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1